Shaily Engineering Plastics Q1 FY27 Results

Revenue: ₹280.7 Crore
PAT: ₹48.0 Crore

Reader Takeaway: Strong healthcare growth offsets consumer slowdown, margins improve.

What just happened

Shaily Engineering Plastics Ltd. announced its financial results for the first quarter of FY27 (ended June 30, 2026). The company reported a 14% year-on-year increase in revenue, reaching ₹280.7 crore. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) grew by 18% to ₹83.3 crore, with EBITDA margins expanding to 29.7%. Profit After Tax (PAT) saw a 17% rise to ₹48.0 crore from ₹41.1 crore in the previous year's Q1.

Why this matters

This performance indicates robust top-line growth driven by operational efficiency and strong segment-specific demand. The improved profitability and margin expansion are positive signs for shareholder value, demonstrating the company's ability to manage costs and leverage growth opportunities effectively.

The backstory

In the previous fiscal year, Shaily Engineering Plastics focused on diversifying its revenue streams and enhancing its product portfolio. The company has been strategically expanding its presence in the healthcare sector, aiming to capitalize on the growing demand for medical devices and components.

What changes now

The company's strategic focus on the healthcare segment appears to be yielding significant results, with an 85% surge in revenue for this vertical. This growth is instrumental in compensating for a 24% decline in the consumer segment, which was impacted by weaker market demand for home furnishings in Europe and the USA. The industrial segment also showed healthy growth of 25%.

Risks to watch

While the healthcare segment is a strong growth driver, the decline in the consumer segment due to external market conditions presents a risk. Dependence on specific export markets for consumer goods could impact future performance if demand does not recover. Sustaining the high growth in healthcare is also crucial.

Peer comparison

[Peer comparison data is not available in the provided filing text.]

Context metrics (time-bound)

Machine utilization across plants stood at 50.2%, up 150 basis points. Exports accounted for 58.1% of revenue, influenced by healthcare segment growth. Return on Capital Employed (RoCE) improved to 39.0% as of June 2026.

What to track next

Investors will be keen to observe the continued growth momentum in the healthcare segment, new customer approvals, and the potential recovery in the consumer business. Monitoring the company's efforts to diversify markets and product offerings will also be important.